过敏反应:布莱顿合作组织病例定义修订版
布莱顿合作组织(BC)基于文献综述和专家共识修订了2007年过敏反应病例定义,重新评估主要和次要标准,强调可观察临床体征而非主观症状,并提供更明确的确定性分级方法,同时与国际其他当代过敏反应病例定义保持一致。
要点
- BC修订过敏反应病例定义,重新评估主要和次要标准。
- 修订强调报告可观察临床体征而非主观症状。
- 提供更明确的确定性分级方法,并与其他国际定义保持一致。
核心结论
- BC提出修订版过敏反应病例定义,重新评估主要和次要标准,强调可观察临床体征,提供更明确的确定性分级方法,并与其他当代国际过敏反应病例定义保持一致。
研究设计与样本
- BC召开专家工作组,基于其常规文献综述和专家共识流程修订2007年BC过敏反应病例定义。
主要发现
- 修订版重新评估了主要和次要标准,重点在于报告可观察临床体征而非主观症状。
- 修订版提供了更明确的确定性分级方法。
- BC病例定义已与其他当代国际过敏反应病例定义保持一致。
关键数值与推荐
- 原文未报告具体的主要和次要标准条款及确定性分级数值。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Brighton Collaboration (BC) has formulated a number of case definitions which have primarily been applied to adverse events of special interest in the context of vaccine safety surveillance. This is a revision of the 2007 BC case definition for anaphylaxis. Recently, the BC definition has been widely used for evaluating reports of suspected anaphylaxis following COVID-19 vaccination. This has led to debate about the performance of the BC definition in comparison with those from the US National Institute of Allergy and Infectious Disease/Food Allergy Anaphylaxis Network (NIAID/FAAN) and the World Allergy Organization (WAO). BC convened an expert working group to revise the case definition based on their usual process of literature review and expert consensus. This manuscript presents the outcome of this process and proposes a revised case definition for anaphylaxis. Major and minor criteria have been re-evaluated with an emphasis on the reporting of observable clinical signs, rather than subjective symptoms, and a clearer approach to the ascertainment of levels of certainty is provided. The BC case definition has also been aligned with other contemporary and international case definitions for anaphylaxis.
引用
- Gold MS, Amarasinghe A, Greenhawt M, et al. Anaphylaxis: Revision of the Brighton collaboration case definition. Vaccine. 2022. PMID: 36435707. doi:10.1016/j.vaccine.2022.11.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。